在持续的药理抑制P-TEFb激酶活性后,Brd4依赖的CDK9表达诱导
1Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
抑制正转录延长因子b (P-TEFb) 活性会增加CDK9的表达,这一过程依赖于Brd4. 联合抑制Brd4和CDK9抑制了瘤细胞的生长,这表明了潜在的治疗策略.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 阳性转录延长因子b (P-TEFb) 对于转录延长至关重要.
- 通过与蛋白质复合体的动态相互作用来调节P-TEFb的活动.
- CDK9是P-TEFb的激酶子单元.
研究的目的:
- 为了研究对P-TEFb抑制的反应中CDK9表达的调节.
- 探索Brd4在这个监管过程中的作用.
- 评估联合Brd4和CDK9抑制在癌症中的治疗潜力.
主要方法:
- 抑制P-TEFb活动.
- 对CDK9表达的评估.
- Brd4抑制的研究.
- 协同作用药物治疗实验.
- 瘤细胞生长分析.
主要成果:
- 在P-TEFb抑制后诱导CDK9的表达.
- 这种诱导取决于Brd4.
- 联合抑制Brd4和CDK9可以协同抑制P-TEFb的活性.
- 联合抑制也抑制了瘤细胞的生长.
结论:
- Brd4在抑制P-TEFb的反应中调节CDK9的表达起着至关重要的作用.
- 联合抑制Brd4和CDK9代表了癌症治疗的有前途的治疗策略.
更多相关视频
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
Inhibition of Cdk Activity
Positive Regulator Molecules
Negative Regulator Molecules
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
MAPK Signaling Cascades
DNA Damage can Stall the Cell Cycle
